Copyright © Inderes 2011 - present. All rights reserved.

Nightingale Health

2.535

 

EUR

 

-2.12 %

4,604 following

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.

Read more
Market cap
154.45M EUR
Turnover
97.15K EUR
P/E (adj.) (25e)
-9.46
EV/EBIT (adj.) (25e)
-5.78
P/B (25e)
2.22
EV/S (25e)
19.14
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
2.90 EUR
Updated
2025-06-11
Disclaimer
Antti Luiro
Antti Luiro

Head of Nordic ER Development, Analyst

Latest research

Latest analysis report

Released: 2025-06-13

Latest extensive report

Released: 2025-06-13

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Nightingale Health extensive report: The next chapter of the growth story is being written
Extensive research by
Antti Luiro

Nightingale Health extensive report: The next chapter of the growth story is being written

Following the successful Terveystalo cooperation, Nightingale is now increasing its commercial sample volumes with its healthcare partners in Singapore and the US. The company's pilot phase customerships are also in general expected to progress, and we believe the company is actively negotiating new partnerships as well. However, we are now particularly looking for signs of strong growth in commercial sample volumes, which would substantially reduce estimate risks.

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Nightingale H1'FY25: Blood draws again
Research by
Antti Luiro

Nightingale H1'FY25: Blood draws again

Nightingale is just launching the commercial phases with its second and third healthcare partners. The company's comments on the sales pipeline are also promising, and we believe it will announce at least one significant partnership during the current year.

Nightingale Health
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.